Zapping prostate tumors with extra precision: new trial aims for fewer side effects
NCT ID NCT07644598
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase II trial tests a new radiation technique for low to intermediate risk prostate cancer. It uses an MRI-guided 'microboost' to deliver a higher dose to the tumor while lowering the dose to the rest of the prostate. The goal is to see if this approach is safe and causes fewer urinary or bowel side effects. About 58 participants will receive treatment over two weeks and be followed for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (SBRT with microboost)
What this could lead to
If successful, this could offer a more precise, shorter radiation treatment for low to intermediate risk prostate cancer with fewer side effects.
What could go wrong
This is a small, early-phase safety trial (58 people). It may not prove effectiveness, and there is still a risk of urinary or bowel side effects from radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.